Targeting the neural cell adhesion molecule in cancer

Cancer Lett. 2007 Dec 8;258(1):9-21. doi: 10.1016/j.canlet.2007.09.004. Epub 2007 Oct 18.


NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neural Cell Adhesion Molecules / immunology*


  • Antibodies, Monoclonal
  • Neural Cell Adhesion Molecules